Evidence map›Paper›PMID 34504655›Full record

ArticleOncotarget2021

The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series.

Kevin Drenner, Gargi D Basu, Laurie J Goodman, Audrey A Ozols, Janine R LoBello, Thomas Royce, Michael S Gordon, Erkut H Borazanci, Margaux A Steinbach, Jeffrey Trent and 1 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kevin DrennerTranslational Genomic Research Institute (Tgen), Phoenix, AZ 85004, USA.
Gargi D BasuAshion Analytics, LLC, Phoenix, AZ 85004, USA.
Laurie J GoodmanAshion Analytics, LLC, Phoenix, AZ 85004, USA.
Audrey A OzolsAshion Analytics, LLC, Phoenix, AZ 85004, USA.
Janine R LoBelloAshion Analytics, LLC, Phoenix, AZ 85004, USA.
Thomas RoyceAshion Analytics, LLC, Phoenix, AZ 85004, USA.
Michael S GordonHonorHealth Research Institute, Scottsdale, AZ 85258, USA.
Erkut H BorazanciHonorHealth Research Institute, Scottsdale, AZ 85258, USA.
Margaux A SteinbachHonorHealth Research Institute, Scottsdale, AZ 85258, USA.
Jeffrey TrentTranslational Genomic Research Institute (Tgen), Phoenix, AZ 85004, USA.
Sunil SharmaTranslational Genomic Research Institute (Tgen), Phoenix, AZ 85004, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe present seven cases of advanced cancer patients who initially underwent tumor testing utilizing smaller, panel-based tests, followed by a variety of therapeutic treatments which ultimately resulted in progression of their disease. These cases demonstrate the value of utilizing WES/RNA seq and characterization following disease progression in these patients and the determination of clinically targetable alterations as well as acquired resistance mutations. MATERIALS AND

methodsAll patients are part of an IRB approved observational study. WES and RNA sequencing were performed, using GEM ExTra

resultsThe presented cases demonstrate the clinical impact of actionable findings uncovered using GEM ExTra

conclusionsTaken together our results demonstrate that GEM ExTra

Indexed as

genomic alterationprecision medicinerare mutationsRNA sequencingwhole exome sequencing

Identifiers

PMID34504655
PMCPMC8416559

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.